NetraMark Engages AM Public Relations for Strategic Communications

NetraMark Holdings Inc., an artificial intelligence (AI) company focused on transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, announced its engagement with AM Public Relations to enhance strategic communications and market awareness for its proprietary NetraAI platform and clinical development initiatives. The Toronto-based firm highlighted this agreement as a crucial part of its strategy to convey its scientific and commercial advancements to a broader audience.

NetraMark, listed on the TSX under the symbol AIAI, and also traded on OTCQB as AINMF and Frankfurt as PF0, has partnered with AM Public Relations, a healthcare-focused agency specializing in media relations, thought leadership, and strategic communications for healthcare and technology companies. George Achilleos, CEO of NetraMark, emphasized that this engagement comes at a pivotal time as the company continues to build awareness for its platform, partnerships, and the significant role NetraAI can play in helping pharmaceutical and biotechnology firms extract more meaningful insights from clinical trial data.

As the market increasingly recognizes the necessity of explainable AI in drug development, NetraMark believes it is vital to communicate its progress clearly and consistently to the appropriate audiences. This strategic move is anticipated to bolster the company's market visibility and investor confidence. Shares of NetraMark (AIAI) have demonstrated positive momentum recently, reflecting a growing enthusiasm for AI-driven healthcare innovation. The broader pharmaceutical sector is progressively adopting AI for clinical research solutions, driving a demand for improved efficiency in trial design, patient selection, and data analysis.

The role of artificial intelligence in drug development is becoming paramount, enabling companies to work with smaller datasets, accurately segment diseases into distinct subtypes, and precisely classify patients for drug sensitivity and treatment efficacy. NetraMark's proprietary NetraAI platform is specifically designed to identify “Model-Derived Subgroups,” which are patient profiles that can optimize dose selection, enhance patient stratification, and inform critical future development decisions. This aligns with the global trend towards more efficient and precise drug discovery and development, fueled by technological advancements and the escalating complexity of clinical trials.

The collaboration with AM Public Relations forms part of NetraMark's broader communications strategy, aimed at supporting its strategic objectives and expanding its industry relationships. The company has showcased increasing adoption of its NetraAI platform, having signed its ninth commercial contract since the beginning of its current fiscal year. This trajectory suggests a continued focus on commercial expansion and market penetration for its AI solutions within the biopharmaceutical sector. Analysts are closely monitoring the potential of NetraMark's NetraAI platform to transform clinical trials and drug development processes.